RxDoctor Payments Data

Sean Moran, MD

Internal Medicine · Lufkin, TXNPI 1093880742

Payments from drug & device makers

$1,566in general payments, 2019–2025

Across 79 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$260
  • Amgen$237
  • Novartis$203
  • Dexcom, Inc.$130
  • Sumitomo Pharma America, Inc.$109
  • Boehringer Ingelheim$108
  • plus $519 from 10 others

What the payments were for

  • Food & beverage$1,55299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,566 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$444,797
Medicare patients
418
Services billed
6,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$114,509
XareltoRivaroxaban95$79,632
OzempicSemaglutide61$68,994
JardianceEmpagliflozin65$61,251
JanuviaSitagliptin Phosphate65$49,479
MounjaroTirzepatide45$44,697
Tresiba Flextouch U-100Insulin Degludec26$12,719
GemtesaVibegron24$12,271
Breo ElliptaFluticasone/Vilanterol13$8,088
RytaryCarbidopa/Levodopa14$7,475
MyrbetriqMirabegron11$6,672
Levothyroxine Sodium553$6,664
Tiotropium Bromide12$4,776
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$4,330
Advair HfaFluticasone Propion/Salmeterol12$4,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$114,509151 claims
Novo NordiskOzempic$260$68,99461 claims
Boehringer IngelheimJardiance$108$61,25165 claims
MerckJanuvia$89$49,47965 claims
Lilly USA, LLCMounjaro$84$44,69745 claims
Sumitomo Pharma America, Inc.Gemtesa$109$12,27124 claims
GSKBreo Ellipta$28$8,08813 claims
Sanofi-aventis U.S. LLCLantus$14$2,30017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →